Active Aero in F1: Explained for Drivers & Fans
- Almost every driver who has run so far during the Formula 1 shakedown in Barcelona came up with the same line after climbing out of the car: "It's...
- That starts with the fact that the 2026 cars have considerably less downforce, and less downforce usually means more complaints from the person behind the wheel.
- A second factor that plays a role in the drivers' perception is the extra workload.
Almost every driver who has run so far during the Formula 1 shakedown in Barcelona came up with the same line after climbing out of the car: “It’s very different from what we’re used to.”
That starts with the fact that the 2026 cars have considerably less downforce, and less downforce usually means more complaints from the person behind the wheel. The FIA, however, hopes that this, combined with reduced dirty air, will benefit the overall racing.
Active aero and partial active aero: How it works
Table of Contents
A second factor that plays a role in the drivers’ perception is the extra workload. They have to do more in the cockpit than before, starting with active aerodynamics. on the straights, the rear wing opens up to reduce drag and the second and third elements of the front wing flatten out. All of this is necessary to make the new power unit formula work.
The so-called ‘Activation Zones’ will be defined for each track, as is described in Article B7.1.1 of the 2026 regulations:
“The FIA will provide all competitors with relevant data regarding the defined Activation Zone(s) for a circuit… to be used when full activation of the Driver Adjustable Bodywork is enabled, and specification of the Activation Zones to be used when only partial activation of the Driver adjustable Bodywork is enabled, no less than four weeks prior to the start of the relevant competition.”
Article B7.1.1f further clarifies that these zones will be indicated in a similar way to how DRS was previously: “The start of each defined Activation Zone shall be marked by a signage on at least one side of the circuit.”
This third option was added to the regulations at the end of last year for use in poor conditions – for example in the rain – and means only the front wing adopts ‘straight line mode’, while the rear wing remains in its closed cornering mode - just like how DRS was disabled in wet conditions.
Tactical thinking with more electrical power
In addition to this, two other aspects come into play for the drivers: Overtake Mode, a kind of push-to-pass system that replaces DRS as an overtaking aid, and above all managing the increased share of electrical power.
With 350 kW coming from the MGU-K, drivers have much more electric power at their disposal and to play with than before. This will become a tactical element to some extent, as where exactly will drivers recharge (harvest) and where will they deploy more energy?
Some F1 team bosses have predicted overtaking in unusual places for precisely that reason, but in practice it truly seems more likely that all teams will converge towards a similar strategy for a given circuit – so they do not end up a sitting duck at the most vulnerable spots.
The Inflation Reduction Act (IRA), signed into law on August 16, 2022, allows Medicare to negotiate prices for certain high-cost prescription drugs, aiming to lower healthcare costs for seniors and taxpayers. This marks a significant shift in Medicare’s longstanding prohibition against direct drug price negotiation.
For decades, Medicare was barred from directly negotiating drug prices with pharmaceutical companies. This prohibition,established in the Medicare Modernization Act of 2003,contributed to rising drug costs. The IRA amends this law, permitting the secretary of Health and Human Services (HHS) to select drugs for negotiation based on factors like high Medicare spending and lack of generic or biosimilar competition. Negotiations began in 2023, with the negotiated prices taking effect in 2026.
On September 1, 2023, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs selected for Medicare price negotiation. CMS Press Release. These drugs treat conditions like diabetes,heart failure,and blood clots.
How Medicare Drug Price Negotiation Works
Medicare drug price negotiation under the IRA is a phased-in process, starting with a small number of drugs and expanding over time.
The process involves several key steps: CMS identifies eligible drugs, manufacturers submit offers, and CMS negotiates to reach a maximum fair price. if a manufacturer refuses to negotiate or doesn’t offer a price CMS deems fair, they face a significant excise tax – 65% on sales of the drug, rising to 95% after 90 days.The negotiated prices apply to Medicare Part D and medicare Part B,covering both prescription drugs dispensed through pharmacies and those administered by healthcare professionals.
The Congressional Budget Office (CBO) estimated that the IRA’s drug pricing provisions would save the federal government approximately $101.8 billion over ten years. However, the pharmaceutical industry has challenged the law in court, arguing it violates the Fifth Amendment’s takings clause.
Drugs Eligible for Negotiation
The IRA specifies criteria for drugs eligible for negotiation.
Eligible drugs must be single-source brand-name drugs – meaning they lack generic or biosimilar competition – and have been on the market for a certain period. Initially, the law allows negotiation for drugs that have been on the market for nine years after FDA approval (for drugs approved before 2026) and 7 years for drugs approved after 2026. The number of drugs subject to negotiation increases over time, from 10 in 2026 to 20 in 2029 and beyond. Drugs protected by orphan drug exclusivity, or with low Medicare spending, are excluded.
The first 10 drugs selected for negotiation in 2023 include medications like Eliquis (apixaban) for blood clots, Jardiance (empagliflozin) for diabetes and heart failure, and Xarelto (rivaroxaban) for blood clots. CMS List of Selected Drugs. These drugs represent a significant portion of Medicare’s total drug spending.
legal Challenges to the IRA
The pharmaceutical industry has launched multiple legal challenges to the IRA’s drug pricing provisions.
Several lawsuits, filed by organizations like the Pharmaceutical Research and Manufacturers of america (PhRMA), argue that the negotiation process violates the Fifth Amendment’s takings clause by effectively forcing manufacturers to sell drugs at prices below a reasonable return on investment. they also contend the law violates due process rights. These cases are currently being litigated in federal courts.
On December 18, 2023, a federal judge in ohio ruled against the pharmaceutical industry, dismissing a lawsuit challenging the constitutionality of the drug price negotiation program. Reuters report on Court Ruling. However, the industry is expected to appeal the decision, and the legal battle is likely to continue.
Impact on Patients and the Healthcare System
The IRA’s drug price negotiation provisions are expected to have a significant impact on patients and the healthcare system.
Lower drug prices for Medicare beneficiaries could lead to reduced out-of-pocket costs and improved access to medications. The CBO estimates that approximately 55 million Medicare beneficiaries will be affected. The savings generated by the IRA could also help to stabilize Medicare’s financial outlook. Though, some analysts warn that the law could lead to reduced investment in research and growth of new drugs, potentially slowing innovation.